Use this link to cite:
http://hdl.handle.net/2183/14871 Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis
Loading...
Identifiers
Publication date
Authors
González-Álvaro, Isidoro
Martínez-Fernández, Carmen
Dorantes-Calderón, Benito
García-Vicuña, Rosario
Hernández-Cruz, Blanca
Herrero-Ambrosio, Alicia
Ibarra-Barrueta, Olatz
Martín-Mola, Emilio
Monte-Boquet, Emilio
Morell-Baladrón, Alberto
Advisors
Other responsabilities
Journal Title
Bibliographic citation
González-Álvaro I, Martínez-Fernández C, Dorantes-Calderón B, García-Vicuña R, Hernández-Cruz B, Herrero-Ambrosio A, Ibarra-Barrueta O, Martín-Mola E, Monte-Boquet E, Morell-Baladrón A, Sanmartí R, Sanz-Sanz J, de Toro-Santos FJ, Vela P, Román Ivorra JA, Poveda-Andrés JL, Muñoz-Fernández S; Spanish Rheumatology Society; Spanish Rheumatology Society. Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford). 2015 Jul;54(7):1200-9.
Type of academic work
Academic degree
Abstract
[Abstract] Objective. The aim of this study was to establish guidelines for the optimization of biologic therapies for health professionals involved in the management of patients with RA, AS and PsA.
Methods. Recommendations were established via consensus by a panel of experts in rheumatology and hospital pharmacy, based on analysis of available scientific evidence obtained from four systematic reviews and on the clinical experience of panellists. The Delphi method was used to evaluate these recommendations, both between panellists and among a wider group of rheumatologists.
Results. Previous concepts concerning better management of RA, AS and PsA were reviewed and, more specifically, guidelines for the optimization of biologic therapies used to treat these diseases were formulated. Recommendations were made with the aim of establishing a plan for when and how to taper biologic treatment in patients with these diseases.
Conclusion. The recommendations established herein aim not only to provide advice on how to improve the risk:benefit ratio and efficiency of such treatments, but also to reduce variability in daily clinical practice in the use of biologic therapies for rheumatic diseases.
Description
Editor version
Rights
This is a pre-copyedited, author-produced PDF of an article accepted for publication in Rheumatology following peer review. The version of the record is avaliable online at Oxford University Press.